Status:
WITHDRAWN
Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct
Lead Sponsor:
Corewell Health East
Conditions:
Coronary Artery Disease
Acute Liver Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Coronary Artery Disease (CAD) is the narrowing or blockage of the artery of the heart and is prevalent in end-stage liver disease. Consultation with cardiologist and stress tests are recommended to pa...
Detailed Description
The purpose of this study is to determine in end-stage liver disease patients whether non-invasive assessment of coronary artery disease prior to liver transplant using CTA (CTA) and CTA-derived Fract...
Eligibility Criteria
Inclusion
- Patients with end-stage liver disease
- Patients undergoing cardiovascular risk assessment prior to liver transplantation -
Exclusion
- Estimated Glomerular Filtration Rate (eGFR) \< 30 cc/min/1.73 m\^2 (unless patient is on dialysis or renal transplant is planned)
- Heart rate \> 90 bpm despite beta blocker therapy
- Body Mass Index (BMI) \> 40 plus chest obesity (i.e. truncal obesity and normal chest morphology is not an exclusion)
- Pregnant Women
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04089969
Start Date
June 1 2023
End Date
June 1 2024
Last Update
March 2 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.